139 related articles for article (PubMed ID: 17235352)
1. The proteasome inhibitor bortezomib acts differently in combination with p53 gene transfer or cytotoxic chemotherapy on NSCLC cells.
Neukirchen J; Meier A; Rohrbeck A; Garcia-Pardillos G; Steidl U; Fenk R; Haas R; Kronenwett R; Rohr UP
Cancer Gene Ther; 2007 Apr; 14(4):431-9. PubMed ID: 17235352
[TBL] [Abstract][Full Text] [Related]
2. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines.
Bae SH; Ryoo HM; Kim MK; Lee KH; Sin JI; Hyun MS
Oncol Rep; 2008 Apr; 19(4):1027-32. PubMed ID: 18357392
[TBL] [Abstract][Full Text] [Related]
3. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer.
An J; Sun YP; Adams J; Fisher M; Belldegrun A; Rettig MB
Clin Cancer Res; 2003 Oct; 9(12):4537-45. PubMed ID: 14555528
[TBL] [Abstract][Full Text] [Related]
4. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
Gordon GJ; Mani M; Maulik G; Mukhopadhyay L; Yeap BY; Kindler HL; Salgia R; Sugarbaker DJ; Bueno R
Cancer Chemother Pharmacol; 2008 Apr; 61(4):549-58. PubMed ID: 17522864
[TBL] [Abstract][Full Text] [Related]
5. Non-small lung cancer cells are prime targets for p53 gene transfer mediated by a recombinant adeno-associated virus type-2 vector.
Rohr UP; Wulf MA; Stahn S; Heyd F; Steidl U; Fenk R; Opalka B; Pitschke G; Prisack HB; Bojar H; Haas R; Kronenwett R
Cancer Gene Ther; 2003 Dec; 10(12):898-906. PubMed ID: 14712316
[TBL] [Abstract][Full Text] [Related]
6. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
Ludwig H; Khayat D; Giaccone G; Facon T
Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003
[TBL] [Abstract][Full Text] [Related]
7. Incorporating bortezomib into the treatment of lung cancer.
Davies AM; Lara PN; Mack PC; Gandara DR
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4647-51. PubMed ID: 17671158
[TBL] [Abstract][Full Text] [Related]
8. Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
Gatti L; Benedetti V; De Cesare M; Corna E; Cincinelli R; Zaffaroni N; Zunino F; Perego P
J Inorg Biochem; 2012 Aug; 113():94-101. PubMed ID: 22717676
[TBL] [Abstract][Full Text] [Related]
9. Proteasome inhibitors in lung cancer.
Scagliotti G
Crit Rev Oncol Hematol; 2006 Jun; 58(3):177-89. PubMed ID: 16427303
[TBL] [Abstract][Full Text] [Related]
10. The potential role of proteasome inhibitors in the treatment of lung cancer.
Bunn PA
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4263s-4265s. PubMed ID: 15217971
[TBL] [Abstract][Full Text] [Related]
11. Schedule-dependent interaction between the proteosome inhibitor bortezomib and the EGFR-TK inhibitor erlotinib in human non-small cell lung cancer cell lines.
Piperdi B; Ling YH; Perez-Soler R
J Thorac Oncol; 2007 Aug; 2(8):715-21. PubMed ID: 17762337
[TBL] [Abstract][Full Text] [Related]
12. A cost-effectiveness analysis of docetaxel versus pemetrexed in second-line chemotherapy for stage IIIb or IV non-small cell lung cancer in China.
Yu YF; Chen ZW; Zhou Z; Song ZB; Li ZM; Jian H; Zhang YF; Lu S
Chemotherapy; 2010; 56(6):472-7. PubMed ID: 21099219
[TBL] [Abstract][Full Text] [Related]
13. Proteasome inhibition with bortezomib enhances activity of topoisomerase I-targeting drugs by NF-kappaB-independent mechanisms.
Takigawa N; Vaziri SA; Grabowski DR; Chikamori K; Rybicki LR; Bukowski RM; Ganapathi MK; Ganapathi R; Mekhail T
Anticancer Res; 2006; 26(3A):1869-76. PubMed ID: 16827119
[TBL] [Abstract][Full Text] [Related]
14. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer.
Weiss GJ; Langer C; Rosell R; Hanna N; Shepherd F; Einhorn LH; Nguyen B; Paul S; McAndrews P; Bunn PA; Kelly K
J Clin Oncol; 2006 Sep; 24(27):4405-11. PubMed ID: 16983108
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer.
Fanucchi MP; Fossella FV; Belt R; Natale R; Fidias P; Carbone DP; Govindan R; Raez LE; Robert F; Ribeiro M; Akerley W; Kelly K; Limentani SA; Crawford J; Reimers HJ; Axelrod R; Kashala O; Sheng S; Schiller JH
J Clin Oncol; 2006 Nov; 24(31):5025-33. PubMed ID: 17075122
[TBL] [Abstract][Full Text] [Related]
16. [Proteasome inhibitor].
Yamamura M; Hirai T; Yamaguchi Y
Nihon Rinsho; 2010 Jun; 68(6):1079-84. PubMed ID: 20535959
[TBL] [Abstract][Full Text] [Related]
17. [Proteasome inhibitors].
Alexandre J
Rev Med Interne; 2005 Oct; 26(10):812-5. PubMed ID: 16129520
[TBL] [Abstract][Full Text] [Related]
18. New developments in chemotherapy for advanced non-small cell lung cancer.
Raez LE; Lilenbaum R
Curr Opin Oncol; 2006 Mar; 18(2):156-61. PubMed ID: 16462185
[TBL] [Abstract][Full Text] [Related]
19. Use of proteasome inhibition in the treatment of lung cancer.
Schenkein DP
Clin Lung Cancer; 2004 Dec; 6 Suppl 2():S89-96. PubMed ID: 15638966
[TBL] [Abstract][Full Text] [Related]
20. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
